Previous studies have verified that NONO-TFE3 fusion inhibits the expression of TRAF3IP2 antisense RNA 1 through directly binding to promoter region to promote the progression of NONO-TFE3 tRCC [20]. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.